” The Companies Cited Increasing Numbers In Covid-19 Infections & Hospitalizations In Children Under The Age Of Twelve.”

October 7, 2021 By Joanne Alvarez Reporting For: Englebrook Independent News,

WASHINGTON, DC.- On Thursday, Pfizer and BioNTech announced that they will be seeking Emergency Use Authorization for their Covid-19 Vaccine from The United States Food and Drug Administration for children between the ages of five and eleven.

     Pfizer took to Twitter to share the news, writing: “With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against #COVID19.”

     The news comes just a little over a week after Pfizer-BioNTech submitted clinical trial data from a Covid-19 study in kids five to eleven to The FDA. The Data included recent findings in 2,268 kids ages five to eleven, which suggests a smaller dose was safe, and resulted in neutralizing antibody response.

     The Companies had previously announced that trial results on younger age groups, like children six months to under five years, are expected by the fourth quarter on 2021.